ATE305772T1 - Herstellung von mikrosphären - Google Patents

Herstellung von mikrosphären

Info

Publication number
ATE305772T1
ATE305772T1 AT01116787T AT01116787T ATE305772T1 AT E305772 T1 ATE305772 T1 AT E305772T1 AT 01116787 T AT01116787 T AT 01116787T AT 01116787 T AT01116787 T AT 01116787T AT E305772 T1 ATE305772 T1 AT E305772T1
Authority
AT
Austria
Prior art keywords
emulsion
microspheres
gas
aqueous phase
phase
Prior art date
Application number
AT01116787T
Other languages
English (en)
Inventor
Nobuyuki Takechi
Seiji Ohtani
Akihiro Nagai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE305772T1 publication Critical patent/ATE305772T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01116787T 1995-12-15 1996-12-13 Herstellung von mikrosphären ATE305772T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32769095 1995-12-15

Publications (1)

Publication Number Publication Date
ATE305772T1 true ATE305772T1 (de) 2005-10-15

Family

ID=18201894

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01116787T ATE305772T1 (de) 1995-12-15 1996-12-13 Herstellung von mikrosphären
AT96309136T ATE219662T1 (de) 1995-12-15 1996-12-13 Herstellung von microspheren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96309136T ATE219662T1 (de) 1995-12-15 1996-12-13 Herstellung von microspheren

Country Status (9)

Country Link
US (2) US5851451A (de)
EP (2) EP0779072B1 (de)
JP (1) JP4988660B2 (de)
AT (2) ATE305772T1 (de)
CA (1) CA2192782C (de)
DE (2) DE69635249T2 (de)
DK (1) DK1142567T3 (de)
ES (1) ES2249362T3 (de)
PT (1) PT1142567E (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
KR100354270B1 (ko) * 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DE60136958D1 (de) * 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
CA2432900C (en) 2000-12-21 2007-09-11 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophilic active agents
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
ATE395042T1 (de) * 2001-08-16 2008-05-15 Baxter Int Darreichungsformen welche mikropartikel und treibgas enthalten
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003055470A1 (fr) * 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
ES2605402T3 (es) * 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
WO2004034975A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
AU2003277446A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
SE0301431D0 (sv) 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US8075919B2 (en) * 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
PL196544B1 (pl) * 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
ES2442115T3 (es) 2004-05-12 2014-02-10 Baxter International Inc. Microesferas que contienen oligonucleótidos, su utilización para la preparación de un medicamento para el tratamiento de la diabetes tipo 1
ES2422757T3 (es) 2004-05-12 2013-09-13 Baxter Int Uso terapéutico de microesferas de ácido nucleico
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
EP1987055A1 (de) * 2006-02-10 2008-11-05 Dermagen AB Neue antimikrobielle peptide und deren verwendung
AU2007250558B2 (en) 2006-05-16 2012-10-25 Pergamum Ab Improved antimicrobial peptides
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
US7964574B2 (en) 2006-08-04 2011-06-21 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008060786A2 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
MY148370A (en) 2006-12-18 2013-04-15 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
CN105688191A (zh) 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
ITSA20070024A1 (it) * 2007-07-27 2009-01-28 Univ Degli Studi Salerno Processo continuo per la produzione di microsfere mediante liquidi espansi.
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2259677A4 (de) * 2008-02-29 2011-11-02 Alseres Pharmaceuticals Inc Systemische purinverabreichung zur modulation des axonalen wachstums des zentralnervensystems
WO2010009291A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
ES2809178T5 (es) 2008-09-04 2024-04-29 Amylin Pharmaceuticals Llc Formulaciones de liberación sostenida que usan portadores no acuosos
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB0916578D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
MX352878B (es) 2009-09-28 2017-12-13 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
DK2598553T3 (da) * 2010-07-26 2016-08-01 Univ Geneve Sammensætninger omfattende polymerer fremstillede af 2-hydroxyalkylsyrer
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
KR101989134B1 (ko) 2011-01-19 2019-06-13 칸타르기아 아베 항―ｉｌ１ｒａｐ 항체 및 그의 인간 치료 용도
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB2493540A (en) 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
DK2771320T3 (en) 2011-10-24 2016-10-03 Endo Pharmaceuticals Inc Cyclohexylamines
KR102362358B1 (ko) 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
GB201214169D0 (en) 2012-08-08 2012-09-19 Biostatus Ltd New compounds and uses thereof
PL3071595T3 (pl) 2013-11-19 2019-09-30 Fredax Ab Humanizowane przeciwciało przeciw kalikreinie-2
BR112016013734A2 (pt) 2013-12-16 2017-08-08 Asana Biosciences Llc Composto, composição farmacêutica, kit, e uso de um composto
PL3099317T3 (pl) 2014-01-29 2022-01-03 Enzymatica Ab Trypsyna z dorsza do zastosowania do leczenia zakażeń drobnoustrojowych u osobnika z niedoborem odporności
GB201405784D0 (en) 2014-03-31 2014-05-14 Enzymatica Ab Novel methods, polypeptides and uses thereof
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
MX2017013565A (es) 2015-04-21 2018-02-19 Gtx Inc Ligandos degradadores selectivos del receptor androgénico (sard) y sus métodos uso.
KR20170140291A (ko) 2015-04-21 2017-12-20 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
EP3120866A1 (de) 2015-07-24 2017-01-25 Zymetech ehf. Verwendung von marineserinproteasen zur entfernung, vorbeugung und hemmung der bildung und des wachstums von biofilmen
BR112018006820A2 (pt) 2015-10-05 2018-10-23 Fredax Ab anticorpos anti-psa (5a10) humanizados
CN105287390A (zh) * 2015-11-20 2016-02-03 北京博恩特药业有限公司 一种长效醋酸亮丙瑞林微球及其制备方法
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
ES2910365T3 (es) 2016-04-22 2022-05-12 Alligator Bioscience Ab Nuevos polipéptidos biespecíficos contra CD137
MX2018014016A (es) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR102481319B1 (ko) 2016-06-10 2022-12-26 유니버시티 오브 테네시 리서치 파운데이션 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
GB201611530D0 (en) 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
CA3037748A1 (en) 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
GB201701315D0 (en) 2017-01-26 2017-03-15 Enzymatica Ab Novel treatments
EP3655439A1 (de) 2017-07-20 2020-05-27 Aptevo Research and Development LLC An 5t4 und 4-1bb bindende antigenbindende proteine und zugehörige zusammensetzungen und verfahren
GB201800274D0 (en) 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201801982D0 (en) 2018-02-07 2018-03-28 Enzymatica Ab Novel treatments
KR20210120819A (ko) 2018-05-16 2021-10-07 온크터널 테라퓨틱스 인코포레이티드 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
FR3082842A1 (fr) 2018-06-21 2019-12-27 Veru Inc. Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci
US11253495B2 (en) 2018-11-21 2022-02-22 Yanming Wang Pharmaceutical composition for treating excessive lactate production and acidemia
US20220073635A1 (en) 2018-12-17 2022-03-10 Alligator Bioscience Ab Novel polypeptides
US20220064325A1 (en) 2018-12-17 2022-03-03 Alligator Bioscience Ab Novel polypeptides
GB201909298D0 (en) 2019-06-28 2019-08-14 Colzyx Ab Novel compositions and uses thereof
EP4069374A1 (de) 2019-12-06 2022-10-12 Thoas Fioretos Neuartige wirkstoffe und verwendungen davon
KR102350655B1 (ko) 2020-10-13 2022-01-12 인센 주식회사 테스토스테론-특이적 어피바디 및 이의 용도
GB202016456D0 (en) 2020-10-16 2020-12-02 Colzyx Ab Novel bioactive peptide combinations and uses thereof
GB202018187D0 (en) 2020-11-19 2021-01-06 Univ Southampton Compositions
KR20230123962A (ko) 2020-12-23 2023-08-24 칸타르기아 아베 항-il1rap 항체
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
GB202102709D0 (en) 2021-02-25 2021-04-14 Univ Southampton Compounds
GB202102823D0 (en) 2021-02-26 2021-04-14 Tochikunda Ltd Diagnostic method
WO2022189518A1 (en) 2021-03-09 2022-09-15 Novalysin Ab Antibacterial polypeptides
WO2022263632A1 (en) 2021-06-18 2022-12-22 Alligator Bioscience Ab Novel combination therapies and uses thereof
CN113695370B (zh) * 2021-08-30 2022-06-07 河北科技大学 一种天然低共熔离子液体及其制备方法和应用
CA3237463A1 (en) 2021-11-05 2023-05-11 Alligator Bioscience Ab Novel peptides
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
WO2023166170A1 (en) 2022-03-03 2023-09-07 Targinta Ab Integrin alpha10 antibody
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202212184D0 (en) 2022-08-22 2022-10-05 Univ Southampton Compounds
GB202215115D0 (en) 2022-10-13 2022-11-30 Univ Nottingham VEGF antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2213737A1 (de) 1972-03-22 1973-09-27 Hoechst Ag Lh-releasing hormon mit protrahierter wirkung
NO139560C (no) 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
JPS528375B2 (de) 1973-07-02 1977-03-09
FR2238700B1 (de) 1973-07-24 1977-10-14 Takeda Chemical Industries Ltd
AT347054B (de) 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
JPS5726506B2 (de) 1974-03-08 1982-06-04
DE2438350C3 (de) 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE2438352A1 (de) 1974-08-09 1976-02-26 Hoechst Ag Peptidcyclopropylamide mit lh-rh/fshrh-wirkung
US4010125A (en) 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
NZ181036A (en) 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
NL7611963A (nl) 1975-10-29 1977-05-03 Parke Davis & Co Werkwijze voor het bereiden van nieuwe nonapep- tiden.
US4087390A (en) 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4100117A (en) 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4124577A (en) 1977-06-13 1978-11-07 Warner-Lambert Nonapeptides and methods for their production
US4218439A (en) 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
US4253998A (en) 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4317815A (en) 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US4253997A (en) 1979-12-17 1981-03-03 American Home Products Corporation Anti-ovulatory decapeptides
JPS5692846A (en) 1979-12-27 1981-07-27 Takeda Chem Ind Ltd Tetrapeptide derivative and its preparation
CS230614B1 (en) 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4569967A (en) 1983-10-24 1986-02-11 The Salk Institute For Biological Studies Synthesis of N-substituted peptide amides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0720859B2 (ja) 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JPH01171634A (ja) * 1987-12-26 1989-07-06 Toagosei Chem Ind Co Ltd 水又は水を主体とする液体のカプセルの製造方法
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0582459B1 (de) * 1992-08-07 1998-01-07 Takeda Chemical Industries, Ltd. Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres

Also Published As

Publication number Publication date
DK1142567T3 (da) 2006-02-06
CA2192782A1 (en) 1997-06-16
JP4988660B2 (ja) 2012-08-01
ATE219662T1 (de) 2002-07-15
DE69622006D1 (de) 2002-08-01
DE69622006T2 (de) 2002-10-24
PT1142567E (pt) 2005-11-30
ES2249362T3 (es) 2006-04-01
JP2008291041A (ja) 2008-12-04
DE69635249T2 (de) 2006-07-13
EP0779072B1 (de) 2002-06-26
EP0779072A1 (de) 1997-06-18
DE69635249D1 (de) 2005-11-10
EP1142567A3 (de) 2002-04-24
EP1142567B1 (de) 2005-10-05
US5851451A (en) 1998-12-22
EP1142567A2 (de) 2001-10-10
US6036976A (en) 2000-03-14
CA2192782C (en) 2008-10-14

Similar Documents

Publication Publication Date Title
ATE219662T1 (de) Herstellung von microspheren
CA2277136A1 (en) Particles containing absorbed liquids and methods of making them
EP0235603A3 (de) Verfahren zum Herstellen gleichförmiger Tröpfchen
CA2113901A1 (en) Preparation of microparticles
ES524518A0 (es) Un procedimiento para preparar un agente anti-inflamatorio
DE69233087D1 (de) Verfahren zur Herstellung von Polymerarrays
WO1997041837A3 (en) Microparticles
ATE204469T1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikrokapseln sowie nach diesem verfahren hergestellte mikrokapseln
ES2149613T3 (es) Procedimiento de preparacion de microcapsulas de materias activas recubiertas por un polimero y nuevas microcapsulas obtenidas en particular segun dicho procedimiento.
KR930021261A (ko) 지지된 촉매, 이의 제조방법 및 비닐 아세테이트를 제조하기 위한 이의 용도
FI930672A0 (fi) Foerfarande foer framstaellning av polymermikrokapslar som innehaoller biologiskt aktivt material
AU2386595A (en) Aqueous solvent encapsulation method, apparatus and microcapsules
WO1993015130A3 (en) Process for increasing stability of poly(esteramides)
CA2024228A1 (en) Process for the production of expanded particles of a polyolefin resin
DK0680315T3 (da) Fremgangsmåde til fremstilling af en virusaerosol
CA2391401A1 (en) Method for the production of particles
KR890007789A (ko) 수용성 펩타이드 및 단백질의 생체분해 가능한 마이크로캡슐의 제조방법 및 이 방법에 의해 수득되는 마이크로캡슐
WO1996020972A3 (en) A process for the removal of a ph-basic material from a polyether polyol
CA2276364A1 (en) Novel water-in-oil microencapsulation process and microcapsules produced thereby
MY118174A (en) Process for the preparation of microparticles
ATE164585T1 (de) Kristallisationsverfahren zur herstellung von glycerophosphocholin
EP0248362A3 (en) Process for the production of an active protein from a biologically inactive form
EP0906931A3 (de) Entfernung von Lösungsmitteln aus Tröpfchen einer suspendierten Polymerlösung
RU95121237A (ru) Способ изготовления предохранительных деталей для защиты внутренней конической резьбы
RU96116479A (ru) Сорбент для удаления атерогенных липопротеидов из крови и способ его получения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1142567

Country of ref document: EP